Endra Life Sciences Inc NDRA

$4.88 +0.14 (2.95%)

Valuation

Market cap
7,109,000
Revenue TTM
$0
Net income TTM
$-7,030,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
14,600
Avg volume
35,158
Day's range
$4.69 – $5.18
Shares out
1,500,000
Stochastic %K
67%
Beta
-0.09
Analysts
Sell
Price target
$25.00

Price

Company profile

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as...

Show more

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
734 335 0468
Website
https://endrainc.com
Address
3600 Green Court, Suite 350, Ann Arbor, United States

Latest news

Stocktwits

Redchip Oct 19, 7:45 PM
Noble Africa (NASDAQ: $NDRA) Live Investor Webinar November 4th, at 4:15 PM ET The Noble Africa investor webinar is in a couple short weeks. Management will present the Virginia Gas Project, one of the world’s highest commercially scalable helium resources, as it moves into commercial production in a supply-constrained helium market. Bring your questions on production, expansion financing and the path to value creation. 📋 What’s on the table: ~3% average helium concentration, well above typical conventional reservoirs at less than 0.5% South Africa’s only onshore petroleum production right, held through 94.5%-owned Tetra4, valid through 2042 and renewable for 30 more years Indicated Phase 2 debt support of up to $500M from the DFC and up to $250M from SBSA (non-binding) A leadership team headed by Paul Mann, who built ASP Isotopes into a $1B+ Nasdaq-listed company Register now to join the live presentation on Nov 4. 🔗 Register here: https://redchip.news/4jv6ZAq #NDRA #NobleAfrica #RedChip
0 replies
Yagangsta Oct 15, 12:42 AM
$NDRA stay far away from this, Paul Mann is a crook
0 replies
chicharrotrading Oct 13, 12:46 PM
$PCSA $NDRA 🔥 today's watchlist — 1 micro/nano-cap + 1 micro/nano-floater covered below. $PCSA (#17) 🚀 strong momentum, ⚠️ elevated risk | Healthcare/Biotechnology ($5.3M) 🔦 Chart flags a recent MACD/Signal crossover — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 Trade policy Export controls Currency fluctuations Regional stability — 📰 Processa Pharmaceuticals Proposes Reverse Stock Split Following Merger with Vidya Therapeutics (Kalkine Media) $NDRA (#10) ⚠️ elevated risk | Healthcare/Diagnostics & Research ($7.7M) — Float 1.4M sh shares 📊 continuation structure characterised by lower highs and lower lows — 🔦 Chart flags a recent test of the reference support level — 🏭 FDA decision cycles Patent-cliff timing Health-policy debates — 🌍 Central-bank policy stance Interest-rate expectations Risk appetite — 📰 187,169 warrant shares are part of ASP Isotopes' stake in ENDRA Life Sciences (NDRA). (Stock Titan)
0 replies
ZacksResearch Sep 30, 2:28 PM
📊 $NDRA Q2: The profit headline comes with a bigger question — liquidity. 🟣 ENDRA swung to $160K of net income from a $1.2M loss, with the improvement driven largely by digital asset gains rather than core business growth. 🏦 The company ended Q2 with $1.7M in cash, $3.8M in restricted cash and a $1.9M Digital Asset Treasury, while operating cash burn improved to $0.9M. 🎯 Now, the spotlight shifts to TAEUS commercialization, regulatory milestones, partnerships and cash runway. Find more on NDRA here 👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39757&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39757
0 replies
FoolAuto Sep 28, 10:50 AM
$ASPI Why would you want $QLE shares then? Just look at $NDRA (which wasn't a spin-off) has only 1.5M shares, and the average volume is low. $ASPI gets most of the benefit from $NDRA results, just as you believe will occur with $QLE. $NDRA and $QLE would function as an operational shell. I'd expect $QLE share price to quickly lose value within a short period after the IPO and languish for 3 to 5 years, just like $ASPI has, as it ramps up from having a test bed for LEU, then LEU+, and then HALEU. The capital outlays for these test beds won't be cheap.
2 replies
Yagangsta Sep 24, 9:36 PM
$NDRA a week of advertising on CNBC and no rally, Paul Mann is a scoundrel
0 replies
Smokeythebear15 Sep 20, 2:32 PM
$NDRA
0 replies
ZacksResearch Sep 18, 10:42 AM
📊 $NDRA Q2: Profit grabbed the headlines, but liquidity may matter more. 🟣 ENDRA posted $160K net income, reversing a $1.2M loss from last year, helped primarily by digital asset gains rather than core business growth. 🏦 The company ended the quarter with $1.7M in cash, $3.8M in restricted cash and a $1.9M Digital Asset Treasury, while operating cash burn improved to $0.9M. 🎯 Investors are now watching TAEUS commercialization, regulatory progress, partnership announcements and runway updates as the next key catalysts. Find more on NDRA here👉 https://www.zacks.com/stock/quote/NDRA?cid=sm-stocktwits-0-quote_overview-oc-39615&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39615
2 replies